Recent trials have highlighted the potential of oral antiviral VV116 in
addressing mild COVID-19 patients. However, there are presently no
comprehensive studies to assess the safety and efficacy of VV116. Thus,
we conducted a systematic review to assess the safety and efficacy for
VV116. A comprehensive search was conducted in PubMed, Scopus database,
and Google Scholar website, with a cut-off date of March 23, to identify
pertinent studies. The results from the three included studies indicated
that no serious adverse events were reported in the VV116 experimental
groups, which exhibited a 2.57-day faster time to viral shedding than
the control group and demonstrated non-inferiority to the
Nirmatrelvir-Ritonavir control group in alleviating major symptoms.
Collectively, the available studies suggest a reliable safety and
efficacy profile for VV116. However, the limited number of three trials
is insufficient for meta-analysis, and the included population consists
of younger individuals with mild and moderate symptoms, not encompassing
the elderly who are severely impacted by COVID-19. We hope that more
studies will be conducted in the future to ensure that VV116 has a more
reliable safety and efficacy profile in the clinical setting, especially
for severe or critical patients.